MIR4443 is a microRNA that has been identified as one of the most highly expressed in non-SC-EVs, suggesting a significant role in extracellular vesicle biology [PMC9800941]. It is associated with a better prognosis in certain conditions, as indicated by a systematic review and meta-analysis [PMC7827149]. Bioinformatics analyses have identified METTL3 as a target gene of MIR4443, implicating it in the regulation of gene expression [PMC9617873]. MIR4443 is also one of the miRNAs that are upregulated and associated with better prognosis, distinguishing it from other miRNAs that are linked to poor prognosis [PMC6830093]. The expression profile of MIR4443 has been assessed using RT-qPCR, highlighting its relevance to hepatocellular carcinoma (HCC) research [PMC7035418]. Although its specificity to Graves' disease (GD) has not been fully explored in other autoimmune diseases, MIR4443's role in GD has been acknowledged [PMC5671953]. Importantly, MIR4443 has been shown to inhibit cisplatin-induced ferroptosis by regulating AIFM2 expression through an m6A-dependent mechanism, suggesting its potential therapeutic implications [PMC8572460].
- g g -- C U g u ggggUUGGA GG GUGGGUU U | | ||||||||| || ||||||| c a ucccgaucu cc uauccaa a a g g uu c g
Disease | Description | Category | PubMed ID |
---|
Accession | MIMAT0018961 |
Description | Homo sapiens hsa-miR-4443 mature miRNA |
Sequence | 9 - UUGGAGGCGUGGGUUUU - 25 |
Evidence |
experimental
Illumina [1] |
Database links |
![]() ![]() ![]() |
Predicted targets |
![]() ![]() ![]() |
|